Boston Life Sciences, Inc. Announces Data to be Presented on Cethrin(R) for Spinal Cord Injury at the 2007 American Association

HOPKINTON, Mass., April 12  /PRNewswire-FirstCall/ -- Boston Life Sciences (NASDAQ:BLSI), a biopharmaceutical company focused on the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders, announces the presentation of 6-month Phase I/IIa clinical data for Cethrin in Acute Spinal Cord Injury (SCI) at the American Association of Neurological Surgeons Annual Meeting April 14-19, 2007 in Washington, DC.

The oral presentation, "Results of the Cethrin Phase I/IIa Prospective Clinical Trial of a Rho Inhibitor for the Treatment of Acute Spinal Cord Injury," will be presented in the Neurotrauma and Critical Care Scientific Session on Monday, April 16, 2007 at 3:15 EDT by Michael G. Fehlings, MD, PhD, FRC, Medical Director of the Krembil Neuroscience Center and Head of the Spinal Program at the University Health Network of the University of Toronto.

About Cethrin

Cethrin is a recombinant protein drug intended to facilitate the re-growth of axons during the critical period immediately after a major injury to the spinal cord. Following an SCI, about two-thirds of patients undergo decompression/stabilization surgery. In this surgery, Cethrin is delivered in a single dose directly onto the injured region of the spinal cord without the need for further invasive procedures.

About Boston Life Sciences

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinson's Disease (PD). The company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston.

  Contact:  Sharon Correia - 508-497-2360
            Boston Life Sciences, Inc.
            

DATASOURCE: Boston Life Sciences, Inc.



CONTACT:  Sharon Correia of Boston Life Sciences, Inc., [phone],





Web site:  http://www.bostonlifesciences.com/

Copyright